Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × fluciclovine F-18 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 19 Brain Neoplasms 10 Glioblastoma 5 Glioma 4 Neoplasms 3 Uterine Cervical Neoplasms 2 Urogenital Diseases 2 Disease 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostate Adenocarcinoma 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma, Follicular 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Lobular 1 Breast Neoplasms 1

Interventions

Dexamethasone 801 Bortezomib 442 Lenalidomide 429 Cyclophosphamide 335 Melphalan 249 Calcium Dobesilate 236 daratumumab 216 pomalidomide 197 carfilzomib 180 fludarabine phosphate 130 Thalidomide 121 fludarabine 118 Peripheral Blood Stem Cell Transplantation 117 Filgrastim 111 ixazomib 85 Mycophenolic Acid 85 Granulocyte Colony-Stimulating Factor 84 Busulfan 83 Whole-Body Irradiation 80 Tacrolimus 75 dexamethasone acetate 74 Cyclosporine 67 Prednisone 64 dexamethasone 21-phosphate 63 isatuximab 60 elotuzumab 59 auricularum 57 Antilymphocyte Serum 55 belantamab mafodotin 53 Etoposide 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06103838 2026-04-14

18F-Fluciclovine PET/CT in Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡